1. Home
  2. LITM vs SCYX Comparison

LITM vs SCYX Comparison

Compare LITM & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LITM
  • SCYX
  • Stock Information
  • Founded
  • LITM 2018
  • SCYX 1999
  • Country
  • LITM Canada
  • SCYX United States
  • Employees
  • LITM N/A
  • SCYX N/A
  • Industry
  • LITM Other Metals and Minerals
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LITM Basic Materials
  • SCYX Health Care
  • Exchange
  • LITM Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • LITM 26.7M
  • SCYX 28.5M
  • IPO Year
  • LITM 2021
  • SCYX 2014
  • Fundamental
  • Price
  • LITM $4.70
  • SCYX $0.74
  • Analyst Decision
  • LITM
  • SCYX
  • Analyst Count
  • LITM 0
  • SCYX 0
  • Target Price
  • LITM N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • LITM 303.1K
  • SCYX 188.8K
  • Earning Date
  • LITM 04-10-2025
  • SCYX 08-07-2025
  • Dividend Yield
  • LITM N/A
  • SCYX N/A
  • EPS Growth
  • LITM N/A
  • SCYX N/A
  • EPS
  • LITM N/A
  • SCYX N/A
  • Revenue
  • LITM N/A
  • SCYX $2,630,000.00
  • Revenue This Year
  • LITM N/A
  • SCYX $410.22
  • Revenue Next Year
  • LITM N/A
  • SCYX $248.83
  • P/E Ratio
  • LITM N/A
  • SCYX N/A
  • Revenue Growth
  • LITM N/A
  • SCYX N/A
  • 52 Week Low
  • LITM $1.98
  • SCYX $0.66
  • 52 Week High
  • LITM $24.44
  • SCYX $2.28
  • Technical
  • Relative Strength Index (RSI)
  • LITM 67.09
  • SCYX 46.93
  • Support Level
  • LITM $3.66
  • SCYX $0.67
  • Resistance Level
  • LITM $4.32
  • SCYX $0.83
  • Average True Range (ATR)
  • LITM 0.34
  • SCYX 0.05
  • MACD
  • LITM 0.10
  • SCYX 0.01
  • Stochastic Oscillator
  • LITM 83.97
  • SCYX 47.06

About LITM Snow Lake Resources Ltd.

Snow Lake Resources Ltd is a Canadian clean energy exploration company with a world-wide portfolio of clean energy mineral projects comprised of two uranium projects and two hard rock lithium projects. Its Projects include: The Black Lake Uranium Project, the Engo Valley Uranium Project, The Shatford Lake Project, and the Snow Lake Lithium Project.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: